Hydroxytyrosol Lowered Aging Markers in UVA-Exposed Skin Cells

Hydroxytyrosol is the olive polyphenol that carries most of the research file, and in 2018 two researchers in South Korea put it in front of a question nobody had asked it before: what does it do to a skin cell under ultraviolet stress? Writing in Biomedical Dermatology, Seeun Jeon and Mina Choi exposed cultured human dermal fibroblasts to UVA and then measured a cellular aging marker, two collagen-degrading enzymes and three inflammatory signals. Cells given hydroxytyrosol before the UVA read lower on every one, and the higher of the two concentrations moved each marker further than the lower. All of it happened in a culture dish, so the work describes what the compound does to cells rather than what it does to skin.

Why This Study Matters

Olive polyphenol research is concentrated on what happens after swallowing. Blood lipids, oxidative markers, artery function, cognition, mortality: the literature is deep on the inside of the body and thin at the surface of it. The authors make that gap their opening argument. At the time they wrote, hydroxytyrosol had been studied in food, medicine and pharmacology. The closest skin work had put a phenolic fraction of olive leaf on keratinocytes and melanoma cells, rather than the isolated compound on the cells that build the dermis.

Dermal fibroblasts are a deliberate choice for that question. They are the cells that manufacture and maintain the collagen and elastin scaffolding beneath the skin surface, and photoaging is largely a story about that scaffolding coming apart faster than it gets rebuilt. Matrix metalloproteinases are the enzymes doing the dismantling. MMP-1 cuts collagen types 1, 2 and 3; MMP-3 works across a wider set of the surrounding matrix, including laminin, fibronectin and collagen types 3 and 4. Ultraviolet exposure raises both.

The sequence the researchers chose gives the result its shape. Hydroxytyrosol went into the culture medium six hours before the UVA lamp came on. That makes the experiment a test of whether the compound blunts damage as it arrives, not a test of whether it repairs damage already done. The distinction matters for how the finding gets quoted, and it is the first thing to hold on to.

How It Was Designed

Human dermal fibroblasts were purchased from a commercial supplier and grown in standard conditions: Dulbecco's modified Eagle medium with 10 percent fetal bovine serum and 1 percent penicillin and streptomycin, at 37 degrees Celsius under 5 percent carbon dioxide. Hydroxytyrosol at a purity above 90 percent was dissolved in dimethyl sulfoxide and added to the medium for a six hour pre-treatment. The culture medium was then removed, the cells were rinsed twice in phosphate-buffered saline and covered with 1 mL of saline to keep them from drying, and UVA was delivered at 8 J per cm2 through the open lid of the dish. Fresh medium went back on and the cells sat for 24 hours before anything was measured.

A toxicity screen came first, which is what sets the dose ceiling for everything that follows. Using a water-soluble tetrazolium assay, survival after 24 hours was 118 percent of untreated cells at 5 micromolar, 106 percent at 10, 97 percent at 20 and 100 percent at 30. The authors concluded that hydroxytyrosol is not cytotoxic to these cells at 30 micromolar or below, then capped the main experiment at 10. A screen like this establishes that the compound is not killing the cells. It measures nothing about the markers that follow.

Two readouts carry the paper. Cellular aging was scored with a senescence-associated beta-galactosidase stain. The enzyme stays active at pH 6.0 in aged cells, while normal cells show that activity only at pH 4.0, and stained cells were counted against total cells under a microscope. Everything else was quantitative real-time PCR, normalized against beta-actin. That second method is worth reading precisely, because PCR counts messenger RNA. It reports how much instruction a cell is issuing for a protein, not how much protein arrived and not how much collagen survived. Each experiment was run three times and the groups compared with unpaired Student's t tests at a threshold of p of 0.05 or below.

What They Found

Each figure is expressed against untreated cells, which are set at 1. The UVA column is the damage the lamp caused on its own. The two hydroxytyrosol columns are cells that received the compound six hours before the same exposure.

Red marks what UVA did on its own; green marks the reading at the higher hydroxytyrosol concentration. Values are fold changes against untreated cells set at 1, averaged over three runs. The authors report the differences as significant at p below 0.05 and mark the figures accordingly; individual p values for each comparison are not given in the text.

Reading the Results

The aging marker moved the most. UVA alone raised senescence-associated beta-galactosidase activity sevenfold. Pre-treatment at 5 micromolar brought it to 4, and 10 micromolar brought it to 2.6. The authors read this carefully in their own discussion, and their phrasing deserves repeating: hydroxytyrosol did not restore the cells, it slowed the progression of the aging signal. A marker that started at 1 and finished at 2.6 is still well above where it began.

The collagen enzymes came back close to baseline. MMP-1 rose 3.18 fold under UVA and sat at 1.14 in cells that had received 10 micromolar, which is nearly the untreated reading. MMP-3 rose further, 5.16 fold, and landed at 1.46. Since these enzymes are the mechanism by which ultraviolet exposure thins the dermal matrix, a drop in their expression is the most direct link the study has to the structural side of photoaging. It is a link at the level of transcription. No collagen was measured in this experiment, in either direction.

The three inflammatory signals moved together. IL-1 beta, IL-6 and IL-8 all rose under UVA and all fell with hydroxytyrosol, in the same dose-dependent pattern. IL-6 had the largest swing, from 6.3 fold under UVA to 1.96. The consistency across three separate genes is what makes the pattern more interesting than any single number in it. Three independent readouts moving the same way is harder to explain by one measurement going astray.

The dose that did the work was the one just below the toxicity screen's floor. Both concentrations produced an effect and the larger one produced more of it, across all six markers, with no reversal at any point. Two data points do not describe a curve, and the experiment never tested whether 20 or 30 micromolar would have continued the trend, flattened it or turned it around.

What the Study Did Not Show

No person took part. Nobody's skin was treated, examined or photographed, and no wrinkle, firmness, hydration, tone or evenness was measured. Olivea makes no claim of that kind, and this paper would not support one if we did.

Nothing was swallowed either. Hydroxytyrosol was pipetted into the fluid surrounding the cells, so the study says nothing about whether eating olive oil or taking a capsule delivers the compound to a fibroblast in living skin, at any concentration. That question is a pharmacokinetic one and this experiment was not built to answer it.

Protein was never measured. Every result except the beta-galactosidase stain is messenger RNA, and gene expression and protein output can diverge. Collagen itself, the thing readers care about when they read about MMPs, was not quantified at all.

The study also ran without a comparison compound. No established antioxidant or dermatological ingredient was tested alongside hydroxytyrosol, so the size of the effect cannot be placed against anything else. And no skin condition was studied: eczema, psoriasis, acne and skin cancer appear nowhere in this work.

Limits and What's Still Unknown

The concentration is the first thing to weigh. Ten micromolar of hydroxytyrosol works out to roughly 1.5 milligrams in a litre of culture fluid, and it sat against those cells continuously for about thirty hours. A swallowed dose behaves nothing like that. The ileostomy study that measured absorption directly found at least 55 to 66 percent of an olive phenol dose taken up, alongside very little of the parent compounds recovered intact. Its authors concluded that olive phenols are extensively modified in the body. What reaches a cell in a person is a changing mixture of metabolites at a falling concentration. What reached these cells was one pure compound held steady.

The experiment is small in the way cell work usually is. One cell type from one commercial source, three runs per condition, two doses tested against UVA, and no independent laboratory has published a replication of it that we could find. Fibroblasts in a dish are also stripped of their context. Real skin puts a stratum corneum, melanin, sebum and a living immune system between the sun and the dermis. It also receives UVA together with UVB in repeated small exposures, rather than a single 8 J per cm2 burst delivered through saline.

The publication route is worth knowing for anyone who wants to check the source. Biomedical Dermatology is an open access journal that is not indexed in PubMed, which is why the link at the end of this page goes to the publisher rather than to a PubMed record as it does elsewhere in our library. The full text is available at no cost under a Creative Commons licence. One author is listed at a company and the other at a university, and the paper declares no competing interests.

The authors' own conclusion is narrower than the headline the study tends to attract. They propose hydroxytyrosol as a candidate cosmetic ingredient deserving of future clinical research. A candidate ingredient in a dish is a long way from a tested product on a face, and the clinical research they called for in 2018 is the part that still has to happen.

Broader Context

Regulation marks the boundary clearly. The one authorized European health claim for olive polyphenols covers protection of blood lipids from oxidative damage, at 5 mg of hydroxytyrosol and its derivatives per 20 g of oil. No regulator in Europe or the United States has authorized a claim about skin, aging or inflammation for olive polyphenols, and cell culture work does not create one. The 2017 EFSA safety opinion covers the compound as a novel food and addresses safety rather than effect.

Human evidence for hydroxytyrosol sits on measurements taken in blood. A 16 week trial at 15 mg a day moved a set of oxidative stress and inflammation markers. EUROLIVE gave 200 men three olive oils differing only in phenolic content and found oxidized LDL falling as that content rose, and an earlier crossover in the same programme reported the same direction on oxidative status. Across dietary polyphenols generally, a cross-sectional study of 315 adults linked higher total plasma polyphenols to 29 percent lower odds of elevated hsCRP, which is an association across all polyphenols rather than an effect of olive oil. None of those trials looked at anyone's skin.

The aging literature is the same shape. An 18 month trial of a polyphenol-rich diet tracked DNA methylation markers related to aging, which are laboratory measures rather than anything visible. Cell-level mechanism work runs alongside it. The 2005 Nature paper on oleocanthal identified an enzyme-inhibiting mechanism shared with ibuprofen in assay conditions. It is a finding of the same type as this one, and it carries the same restriction on how far it can be read.

For skin specifically, this paper joins a small pile of culture experiments rather than a body of trials. Our overview of whether olive oil is good for your skin sets that pile against the diet studies and the one controlled test of plain oil on adult skin. Our guide to hydroxytyrosol in skincare covers the compound as a topical ingredient. The distinction that runs through both is the one this study also draws, between what a compound does to a cell and what a product does to a person.

Related Research

Continue exploring olive oil and polyphenol science:

• What Is Hydroxytyrosol? Olive Oil's Most Studied Compound
• Hydroxytyrosol Improves 7 Biomarkers of Aging and Inflammation
• Hydroxytyrosol Changed Gut Bacteria in Mice, and the Effect Transferred
• Why the EVOO Matrix Matters: 20-Person Bioavailability Trial on Hydroxytyrosol

Source: View the original study at the publisher

Olivea's Dosage

A concentration in a culture dish does not convert into a serving, so this study sets no dietary target and no topical one. Olivea works at dietary scale on the same compound. Each Olivea capsule delivers over 20 mg of hydroxytyrosol, with our most recent third party certificate of analysis confirming 23.5 mg per capsule. Our extra virgin olive oils publish their measured figures, so a high phenolic olive oil can be read against the 5 mg threshold rather than guessed at. A 20 person trial that gave the same 5 mg dose in six different foods found the oil itself delivering it better than yogurt or water. On translating those numbers into a daily amount, see our guide to hydroxytyrosol dosage, and for how the compound converts inside the body, the human trial on tyrosol becoming hydroxytyrosol.

Neither the capsule nor the oil is a skincare product and neither is sold for skin. They are food, measured in milligrams, against a threshold set for blood lipids. Readers looking at the supplement category for skin reasons can see how the ingredients compare in our review of skin supplements.

We share this research for transparency. This is an independent study: we did not fund it, design it, or conduct it, and it did not test an Olivea product.

Editorial Information

Research note. This article summarizes third-party research published in a peer-reviewed journal. Olivea did not conduct or fund the study. Findings reflect the cited paper only and do not establish efficacy of Olivea products.

.